Pain is important for patients with kidney failure, but opioid medication prescriptions are associated with morbidity and mortality. This study found that the opioid prescription rates of patients with ESKD decreased between 2011 and 2020. https://t.co/ghUCE2ETm7
@Tom_Nolin
Gaps in guideline-concordant care for CKD lead to poor outcomes. This study found that K-CHAMP was effective in accelerating implementation of SGLT-2i and GLP-1RA but did not increase ACEi/ARB in patients with albuminuria or moderate-high intensity statin use, or improve blood pressure control, glycemic control, or albuminuria testing in individuals with CKD in the primary care setting. https://t.co/prC50RX7gf
@jgyabes@MitraEpi@Tom_Nolin
Importantly, new @US_FDA renal guidance https://t.co/JTcF5yzRxF will lead to more eGFR based dosing recs and will facilitate clinical implementation of eGFR based medication decisions https://t.co/iHcKlXheLg
Exciting to see consensus recs published on implementation of race-free eGFR-based medication-related decisions! Must read for stakeholders in the kidney disease community. Thank you @nkf for endorsing and @AJHPOfficial for publishing open access @pittpharmacy#nephropharmacology
This newly published primer developed by an @nkf workgroup marks the first significant step in encouraging organizations to implement a more consistent method of accounting for kidney function in treatment decisions. https://t.co/iIOpNfgRE1
Gaps in guideline-concordant care for CKD lead to poor outcomes. This study found that K-CHAMP was effective in accelerating implementation of SGLT-2i and GLP-1RA but did not increase ACEi/ARB in patients with albuminuria or moderate-high intensity statin use, or improve blood pressure control, glycemic control, or albuminuria testing in individuals with CKD in the primary care setting. https://t.co/prC50RX7gf
@jgyabes@MitraEpi@Tom_Nolin
Many thanks for the invitation!
@devlinpharmd
Time for pharmacists to rethink the use of C-G to calculate eCrCl and instead use CKD EPI 2021 non-indexed for drug dosing?
@Tom_Nolin@WendyStPeter002@nkf@ASNKidney@pittpharmacy
Earlier this week, members of the #PittPharmacy community gathered in Maryland — where they shared stories from their time at Pitt Pharmacy, attended the 2024 @ACCP Annual Meeting, & celebrated Dr. Venkat's Distinguished Investigators Award. A proud moment for Pitt Pharmacy! #h2p
A study found ESKD patients��� opioid prescription rates decreased between 2011 and 2020. Mortality risk was monotonically associated with morphine milligram equivalents in patients with kidney failure who received long-term opioid prescriptions https://t.co/xWCqnzkr5s @Tom_Nolin
Congrats to @pittpharmacy’s Dr. Raman Venkataramanan on his well deserved Distinguished Investigator Award from @ACCP1_org! A testament to his remarkable career achievements and legacy of excellence in research. H2P!
Congratulations to Dr. Morgan Butrovich on her successful PhD defense! Her work assessed 1) impact of using various kidney fxn estimation eqtns on anticancer drug selection/dosing, and 2) kinase inhibitor PK in decreased GFR. From @pittpharmacy to the @US_FDA#nephropharmacology
Long-awaited update of @US_FDA Guidance related to Assessment of PK and Drug Dosing in people w/ Impaired Kidney Fxn now issued! Important info RE: determining kidney fxn, assessing PK of nonrenally cleared drugs, and evaluating PK and dosing during CRRT. https://t.co/7QWUt8S24x
Important work to understand the implications of using kidney function estimating equations on drug eligibility, selection, and dosing in different populations. #nephropharmacology@pittpharmacy
Pitt School of Pharmacy has received a five-year, $7.8 million grant to improve quality of care for patients with opioid use disorder across Pennsylvania. @pittpharmacy@NIDAnews
Read more:https://t.co/lGQZzDpocS
Always so exciting to participate in @US_FDA workshops and to meet legends like Drs. George Schwartz, Guido Filler and Saskia de Wildt! ADEPT8 Workshop on Drug Dosing in Pediatric Patients with Renal Impairment https://t.co/ssEtfYJ5Au #nephropharmacology@pittpharmacy
Great work! And a wonderful example of the benefit of leveraging @PittHealthSci Core Research Facilities like the Small Molecule Biomarker Core mass spectrometry facility housed @pittpharmacy to support research. The future is bright in the Devanathan Lab!
Excited to share our publication https://t.co/7qM0xUogbT with @Tom_Nolin (https://t.co/cHP2wJT6nF) and the @RustbeltCFAR about quantifying plasma concentrations of lenacapavir! Plenty of fun #lenacapavir clin PK studies to occur at @pittpharmacy! @GileadSciences@GileadHIV
Excited to unveil @pittpharmacy’s new @Bruker Avance NEO 400 MHz NMR System! An incredible resource that provides unique capabilities and research opportunities. H2P! @PittResearch